Review
Environmental Sciences
Priyanshi Sikka, Tapan Behl, Sanchay Sharma, Aayush Sehgal, Saurabh Bhatia, Ahmed Al-Harrasi, Sukhbir Singh, Neelam Sharma, Lotfi Aleya
Summary: Ω-3 fatty acids are recognized for their benefits on physical and mental health, primarily obtained from fish and fish products. Adequate intake of Ω-3 fatty acids can improve brain function and neuronal function, reduce depressive symptoms, and have fewer side effects compared to antidepressants.
ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH
(2021)
Article
Cardiac & Cardiovascular Systems
Richard L. Weinberg, Robert D. Brook, Melvyn Rubenfire, Kim A. Eagle
Summary: Omega-3 polyunsaturated fatty acids play a key role in heart-healthy diet, and can be obtained through fatty fish consumption or fish oil supplementation. They not only treat hypertriglyceridemia, but also prevent cardiovascular events, with additional benefits such as reducing inflammation and improving plaque stability.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2021)
Article
Nutrition & Dietetics
Bojung Seo, Keming Yang, Ka Kahe, Abrar A. Qureshi, Andrew T. Chan, Immaculata De Vivo, Eunyoung Cho, Edward L. Giovannucci, Hongmei Nan
Summary: This study suggests that higher intakes of DHA and consumption of canned tuna are associated with longer leukocyte telomere length (LTL) in US males.
AMERICAN JOURNAL OF CLINICAL NUTRITION
(2022)
Article
Nutrition & Dietetics
Maria Dolores Mesa, Fernando Gil, Pablo Olmedo, Angel Gil
Summary: This study aims to estimate the amount of n-3 LC-PUFA provided by commonly consumed fishes, shrimps, and mollusks, to conduct a risk-benefit analysis of fish consumption. Consuming 2-3 servings of a variety of fishery products per week can help meet recommended n-3 LC-PUFA levels while maintaining a balance to avoid potential risks from contaminants.
Article
Biochemistry & Molecular Biology
Ines Drenjancevic, Jan Pitha
Summary: In addition to proven medications, omega-3 polyunsaturated fatty acids (n-3 PUFAs) are considered to have additive effects on cardiovascular health. They influence the cardiovascular system through various mechanisms, including effects on metabolism, inflammation, thrombosis, and direct effects on cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Medicine, General & Internal
Safi U. Khan, Ahmad N. Lone, Muhammad Shahzeb Khan, Salim S. Virani, Roger S. Blumenthal, Khurram Nasir, Michael Miller, Erin D. Michos, Christie M. Ballantyne, William E. Boden, Deepak L. Bhatt
Summary: Omega-3 fatty acids reduce cardiovascular mortality and improve cardiovascular outcomes, with higher efficacy observed with EPA monotherapy compared to EPA+DHA combination therapy.
Article
Sport Sciences
Jon-Kyle Davis, Eric C. Freese, Anthony S. Wolfe, Steven A. Basham, Kimberly M. W. Stein
Summary: The study evaluated the omega-3 PUFA blood concentrations, dietary, and supplement intake of 119 professional basketball players, with many players having insufficient fish consumption per week and only a few players supplementing with omega-3 PUFA.
JOURNAL OF STRENGTH AND CONDITIONING RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Juan Li, Meiru Mao, Jiacheng Li, Ziteng Chen, Ying Ji, Jianglong Kong, Zhijie Wang, Jiaxin Zhang, Yujiao Wang, Wei Liang, Haojun Liang, Linwen Lv, Qiuyang Liu, Ruyu Yan, Hui Yuan, Kui Chen, Yanan Chang, Guogang Chen, Gengmei Xing
Summary: This study assessed the effects of omega-3 fatty acids on alleviating inflammation and lung injury induced by PM2.5 inhalation exposure. It was found that oral administration of DHA and EPA effectively restored normal inflammatory cytokine levels and reduced lung parenchymal lesions in mice exposed to PM2.5.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Cardiac & Cardiovascular Systems
Kevin C. Maki, Harold E. Bays, Christie M. Ballantyne, James A. Underberg, John J. P. Kastelein, Judith B. Johnson, James J. Ferguson
Summary: This study compared the efficacy and plasma fatty acid levels of EPA+DPA-FFA and EPA-EE in hypertriglyceridemic patients. The results showed that EPA+DPA-FFA significantly improved plasma levels of EPA, DPA, and total omega-3, while reducing triglycerides and high-sensitivity C-reactive protein without increasing low-density lipoprotein cholesterol.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2022)
Review
Nutrition & Dietetics
Maja Tomczyk, Jeffery L. Heileson, Miroslaw Babiarz, Philip C. Calder
Summary: Fatty fish and certain species of algae are the only natural sources of EPA and DHA, which have various beneficial effects for athletes. Due to limited intake and fluctuating content, athletes may consider using supplements to ensure sufficient EPA and DHA levels.
Review
Nutrition & Dietetics
Meghan Dempsey, Michelle S. Rockwell, Laurel M. Wentz
Summary: The majority of the population lack adequate omega-3 fatty acids (n-3 FA), leading to global deficiencies and poor omega-3 status. This study aimed to evaluate the effect of n-3 FA interventions on omega3-index (O3i) and estimate sufficient intake to meet recommendations.
FRONTIERS IN NUTRITION
(2023)
Article
Nutrition & Dietetics
Stephen W. Farrell, Laura F. DeFina, Nathan L. Tintle, David Leonard, Kenneth H. Cooper, Carolyn E. Barlow, William L. Haskell, Andjelka Pavlovic, William S. Harris
Summary: Both this study and a meta-analysis of similar studies found no evidence to suggest that consuming n-3 PUFA-rich fish or using fish oil supplements affects the risk of prostate cancer.
Article
Nutrition & Dietetics
Gael Nana, Suparna Mitra, Henry Watson, Caroline Young, Henry M. Wood, Sarah L. Perry, Amanda D. Race, Philip Quirke, Giles J. Toogood, Paul M. Loadman, Mark A. Hull
Summary: Oral administration of omega-3 PUFAs leads to increased luminal omega-3 PUFA concentrations and changes to the microbiome in the ileum of individuals with a temporary ileostomy. There is large variability in ileal microbiome over time and between individuals, with no consistent change associated with acute omega-3 PUFA dosing.
JOURNAL OF NUTRITION
(2021)
Article
Nutrition & Dietetics
Peder L. Myhre, Trygve Berge, Are A. Kalstad, Sjur H. Tveit, Kristian Laake, Erik B. Schmidt, Svein Solheim, Harald Arnesen, Ingebjorg Selje, Arnljot Tveit
Summary: Recent clinical trials have raised concerns about the potential adverse effects of n-3 polyunsaturated fatty acid supplementation on atrial fibrillation (AF) risk. This study aimed to assess the risk and potential mediators of AF and 'micro-AF' from n-3 PUFA in post-MI patients. The results showed that supplementation of n-3 PUFA increased the risk of 'micro-AF' and AF, and changes in EPA seemed to play an important role in mediating this effect. Rating: 8 out of 10.
CLINICAL NUTRITION
(2023)
Review
Pharmacology & Pharmacy
Ivana Djuricic, Philip C. Calder
Summary: Long-chain omega-3 fatty acids EPA and DHA are found in seafood, supplements, and concentrated pharmaceutical preparations. Prospective cohort studies show that higher intakes of EPA+DHA or higher levels of EPA and DHA in the body are associated with a lower risk of developing cardiovascular disease (CVD), especially coronary heart disease and myocardial infarction, and cardiovascular mortality in the general population. The cardioprotective effect of EPA and DHA is due to their beneficial modulation of multiple risk factors for CVD.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Ichiro Tatsuno, Kentarou Kudou, Tomoya Kagawa
CARDIOVASCULAR THERAPEUTICS
(2015)
Article
Oncology
Kazuhiro Suzuki, Mikio Namiki, Tsukasa Fujimoto, Nobuyoshi Takabayashi, Kentarou Kudou, Hideyuki Akaza
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2015)
Article
Medicine, Research & Experimental
Yoshikazu Kinoshita, Yuuichi Sakurai, Madoka Shiino, Kentaro Kudou, Akira Nishimura, Takuya Miyagi, Katsuhiko Iwakiri, Eiji Umegaki, Kiyoshi Ashida
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
(2016)
Article
Gastroenterology & Hepatology
Kiyoshi Ashida, Katsuhiko Iwakiri, Naoki Hiramatsu, Yuuichi Sakurai, Tetsuharu Hori, Kentarou Kudou, Akira Nishimura, Eiji Umegaki
WORLD JOURNAL OF GASTROENTEROLOGY
(2018)
Article
Pharmacology & Pharmacy
Ichiro Tatsuno, Yasushi Saito, Kentarou Kudou, Jun Ootake
JOURNAL OF CLINICAL LIPIDOLOGY
(2013)
Article
Obstetrics & Gynecology
Yutaka Osuga, Kazuaki Enya, Kentarou Kudou, Hiroshi Hoshiai
FERTILITY AND STERILITY
(2019)
Article
Gastroenterology & Hepatology
Yoshikazu Kinoshita, Yuuichi Sakurai, Nobuyoshi Takabayashi, Kentaro Kudou, Takahiro Araki, Takuya Miyagi, Katsuhiko Iwakiri, Kiyoshi Ashida
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY
(2019)
Article
Obstetrics & Gynecology
Yutaka Osuga, Yoshifumi Seki, Masataka Tanimoto, Takeru Kusumoto, Kentarou Kudou, Naoki Terakawa
Summary: This study evaluated the efficacy and safety of relugolix in treating endometriosis-associated pain, showing that oral administration of relugolix alleviated pain in a dose-response manner and was generally well tolerated. Relugolix demonstrated efficacy and safety comparable to leuprorelin, another treatment option.
FERTILITY AND STERILITY
(2021)
Article
Oncology
Makoto Nishio, Tatsuya Yoshida, Toru Kumagai, Toyoaki Hida, Ryo Toyozawa, Tadasuke Shimokawaji, Koichi Goto, Kazuhiko Nakagawa, Yuichiro Ohe, Takashi Seto, Kentarou Kudou, Takayuki Asato, Pingkuan Zhang, Nobuyuki Yamamoto
Summary: This study evaluated the efficacy and safety of brigatinib in Japanese patients with ALK-positive NSCLC refractory to alectinib, showing clinically meaningful efficacy and consistent safety profile with broader populations. Brigatinib demonstrated antitumor activity in patients with specific secondary mutations and a significant objective response rate in alectinib-refractory patients.
JOURNAL OF THORACIC ONCOLOGY
(2021)
Article
Public, Environmental & Occupational Health
Yutaka Osuga, Yoshifumi Seki, Masataka Tanimoto, Takeru Kusumoto, Kentarou Kudou, Naoki Terakawa
Summary: The study evaluated the safety and efficacy of relugolix in women with endometriosis-associated pain over a 24-week treatment period. In this phase 2 study, relugolix showed a similar pain reduction effect to leuprorelin, but with a dose-dependent loss in bone mineral density.
Article
Public, Environmental & Occupational Health
Hiroshi Hoshiai, Yoshifumi Seki, Takeru Kusumoto, Kentarou Kudou, Masataka Tanimoto
Summary: This study evaluated the efficacy and safety of different dose levels of the oral GnRH receptor antagonist relugolix in Japanese women with uterine leiomyomas and heavy menstrual bleeding. The results showed a dose-response decrease in menstrual blood loss with relugolix, with generally well-tolerated adverse events.
Article
Pharmacology & Pharmacy
Takayoshi Yamaguchi, Kentarou Kudou, Hiroyuki Okamoto, Chunlin Chen, Roger Whiting, Hisakuni Sekino
Summary: Trazpiroben, a peripherally selective dopamine D-2/D-3 receptor antagonist, showed promising safety and pharmacokinetic profiles in a study involving healthy Japanese men. Results were comparable to a prior trial in healthy individuals from the US, indicating potential for treating chronic gastroparesis across different populations. Ongoing evaluation in a phase IIb study suggests Trazpiroben may be a viable therapy option.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT
(2022)
Article
Gastroenterology & Hepatology
Xiaohua Hou, Fandong Meng, Jiangbin Wang, Weihong Sha, Cheng-Tang Chiu, Woo Chul Chung, Liqun Gu, Kentarou Kudou, Chui Fung Chong, Shutian Zhang
Summary: This study compared the efficacy and safety of vonoprazan and lansoprazole in non-Japanese Asian patients with duodenal ulcers. The results showed that vonoprazan was non-inferior to lansoprazole in healing duodenal ulcers and achieving H. pylori eradication in these patients.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Katsuhiko Iwakiri, Yuuichi Sakurai, Madoka Shiino, Hiroyuki Okamoto, Kentaro Kudou, Akira Nishimura, Naoki Hiramatsu, Eiji Umegaki, Kiyoshi Ashida
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2017)